Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 June;108(3 Suppl 1) > Minerva Medica 2017 June;108(3 Suppl 1):6-12

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEW  XII PNEUMOLAB PROCEEDINGSFREEfree


Minerva Medica 2017 June;108(3 Suppl 1):6-12

DOI: 10.23736/S0026-4806.17.05322-8

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Exploring adjuvant epidermal growth factor receptor inhibition in non-small cell lung cancer

Giulia M. STELLA 1 , Davide PILONI 2

1 Unit of Pulmonology, Fondazione IRCCS, Policlinico San Matteo di Pavia, Pavia, Italy; 2 Department of Internal Medicine, University of Pavia, Pavia, Italy


PDF  


Lung cancer is among the most important causes of death worldwide. Despite the relevant progresses in the personalized approach to lung cancer, patients’ survival is still poor. Only a minor fraction of patients can be addressed to surgery for radical tumor removal. Adjuvant chemotherapy is currently recommended for resected stages II and III patients although it is known that it can modestly contribute to survival prolongation. A better identification of molecular markers, predictive of adjuvant chemo response is now mandatory, in order to reduce useless toxicities and identify those patients who could really benefit. Here we present and analyze a recent paper by Huang et al. aimed at evaluating the prognostic role of epidermal growth factor receptor (EGFR) activation in adjuvant setting in order to determine whether the administration of EGFR tyrosine-kinase inhibitors could improve the outcomes of patients affected by NSCLC undergoing complete resection. Moreover we provide an exhaustive literature revision that could be helpful for a proper management of that small cohort of EGFR-mutated resected NSCLC.


KEY WORDS: Chemotherapy, adjuvant - Epidermal growth factor - Protein kinase inhibitors - Carcinoma, non-small-cell lung - Survival

top of page

Publication History

Issue published online: August 31, 2017
Manuscript accepted: June 29, 2017
Manuscript received: June 23, 2017

Cite this article as

Stella GM, Piloni D. Exploring adjuvant epidermal growth factor receptor inhibition in non-small cell lung cancer. Minerva Med 2017;108(Suppl. 1 to No. 3):6-12. DOI: 10.23736/S0026-4806.17.05322-8

Corresponding author e-mail

g.stella@smatteo.pv.it